Navigation Links
Experimental Drug Helps Fight Aggressive Breast Cancer: Report
Date:1/6/2011

an cancer.

In this study, 123 patients with triple-negative breast cancer were randomized to receive a commonly used, well-tolerated chemotherapy regimen (gemcitabine and carboplatin) or to receive chemo plus iniparib.

More than one-half of the women responded to the combination treatment (meaning the tumor volume decreased) versus only about one-third of those receiving chemo alone.

Women receiving iniparib plus chemo lived an average of 12.3 months compared to just 7.7 months in the chemo-alone group. This may not seen like very long in either group, but for this serious a cancer, it is impressive, the researchers noted.

This was a phase 2 trial. O'Shaughnessy, who is co-director of breast cancer research at Baylor-Sammons Cancer Center, US Oncology, and Texas Oncology in Dallas, said the results of a larger (about 500 patients) phase 3 trial should be available within one to three months.

"The whole field is still preliminary and we have to be careful not to overhype the results [as] we're waiting on the results of the phase 3 trial," she said. "Phase 2 was quite positive, but we really don't know if this is going to end up benefiting patients until we get to phase 3."

In her editorial accompanying the study, Carey agreed. "Both excitement and caution are appropriate in interpreting the trial," she wrote. "Some clear drawbacks should be noted." Among them, she said, were the small size of the study group, "imbalances at baseline" favoring the iniparib group, and the "unconventional" chemotherapy regimen. But caveats notwithstanding, she concluded, the results may herald improved therapy "for an underserved subgroup of patients with breast cancer."

O'Shaughnessy added that the drug was "extremely well tolerated [by patients]. It didn't seem to add any appreciable toxicity to chemotherapy."

In the meantime, she pointed out, a woman walking through a clinic door who is diagnosed with triple-negative breast cancer
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Experimental Drug Offers Hope for Cystic Fibrosis Patients
2. Experimental Vaccine Shields Monkeys Against Ebola
3. Experimental targeted therapy shows early promise against medulloblastomas
4. Experimental nonsteroidal treatment of asthma shows promise
5. Experimental obesity drug avoids brain effects that troubled predecessors
6. Experimental treatments for cocaine addiction may prevent relapse
7. Experimental TB Test Called Fast and Accurate
8. Experimental Drug Shows Promise for Bone Marrow Disorder
9. Experimental Leukemia Drug Proves a Slam Dunk
10. Experimental Test May Spot Prostate Cancer Earlier, More Accurately
11. Experimental Drug Aids Kids With Nervous System Tumor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Helps Fight Aggressive Breast Cancer: Report
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... 17, 2014U.S. military personnel who served in Iraq ... traumatic brain injury (TBI) were compared to military ... medical reasons. Differences in measures of overall disability, ... after injury are reported in an article in ... from Mary Ann Liebert, Inc., publishers. The article ...
(Date:4/17/2014)... a new mechanism that allows blood to enter the ... and the Salk Institute have opened the door to ... damage. , A complex and devastating neurological condition, stroke ... for disability in the U.S. The blood-brain barrier is ... into the brain, causing the permanent deficits in movement ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:New MRSA superbug emerges in Brazil 2
... at the Swedish medical university Karolinska Institutet have discovered ... inflammatory substances in their brains. Their findings offer hope ... affect the immune system. The causes of ... of effective treatments. One theory is that infections caught ...
... stimulates collagen production in fibroblasts and hepatic stellate ... the development of liver fibrosis. Hepatoprotective effects of ... induced liver fibrosis were reported in many studies. ... dimethylnitrosamine (DMN)-induced models has not been studied. ...
... or stall carotid artery disease , WEDNESDAY, Nov. 18 ... no additional benefit to seniors with coronary artery disease ... say. , The 18-month study of 145 Baltimore-area men ... in arterial wall thickness reductions between those who took ...
... quickly is critical, experts say , WEDNESDAY, Nov. 18 ... and communities in new guidelines for treatment of coronary ... should have an organized system of emergency care for ... they get to hospitals and strategies for getting ...
... , ... of the StreetSmarts® sales knowledge sharing platform and ELA’s sales expertise offers a winning ... ... Inc., developer of the on-demand sales effectiveness , knowledge and collaboration ...
... , LONDON, Nov. 18 XL Insurance, the global insurance ... today announced the strengthening of its equine capabilities with the ... Underwriting Limited ("Unicorn"), a subsidiary of THB Group plc. ... who has over 20 years of underwriting experience in the ...
Cached Medicine News:Health News:Immune system activated in schizophrenia 2Health News:Niacin Adds No Benefit for Statin Patients: Study 2Health News:New Heart Attack Treatment Guidelines Stress Coordination 2Health News:New Heart Attack Treatment Guidelines Stress Coordination 3Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 2Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 3Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 4Health News:XL Insurance Strengthens Equine Underwriting Team 2
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Sept. 3 Forest Laboratories, Inc.,(NYSE: ... announced results from,two global Phase III studies ... for the treatment of patients with chronic,obstructive ... I&II,(AClidinium CLinical Trial Assessing Efficacy and Safety ...
... Efficacy ... Endpoints, Company to Host Conference Call and Webcast Wednesday, September ... 8:30 am ET ... NBIX ) today announced positive safety and efficacy results,from its third Phase II clinical ...
Cached Medicine Technology:Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 2Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 3Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 4Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 5Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 6
A convenient, rotating standholds up to seven Gilson pipettes (any model) with exceptional stability. Protects your precious pipettes from possible damage or contamination....
Inquire...
... solution for scheduling, performing and documenting ... pipettes and liquid handling devices. Collects ... Supports all gravimetric calibration protocols ... NCCLS and GLP requirements Includes ...
... V-shaped bottom allows easy withdrawal of solution ... bag ,• Corner pouring lips facilitate ... designed for 4, 8, and 12 channel ... withdrawal of practically all of the solution. ...
Medicine Products: